Connection

Christina Johnson to Cell Line, Tumor

Back to Details
This is a "connection" page, showing publications Christina Johnson has written about Cell Line, Tumor.
Christina Johnson
Connection Strength
0.448
Cell Line, Tumor
  1. Polymer-enhanced delivery increases adenoviral gene expression in an orthotopic model of bladder cancer. J Control Release. 2014 Feb 28; 176:35-43.
    View in: PubMed
    Score: 0.040
  2. Targeting sphingosine kinase induces apoptosis and tumor regression for KSHV-associated primary effusion lymphoma. Mol Cancer Ther. 2014 Jan; 13(1):154-64.
    View in: PubMed
    Score: 0.040
  3. Adenoviral infectivity of exfoliated viable cells in urine: implications for the detection of bladder cancer. BMC Cancer. 2011 May 12; 11:168.
    View in: PubMed
    Score: 0.033
  4. Sorafenib activates CD95 and promotes autophagy and cell death via Src family kinases in gastrointestinal tumor cells. Mol Cancer Ther. 2010 Aug; 9(8):2220-31.
    View in: PubMed
    Score: 0.032
  5. Vorinostat and sorafenib increase CD95 activation in gastrointestinal tumor cells through a Ca(2+)-de novo ceramide-PP2A-reactive oxygen species-dependent signaling pathway. Cancer Res. 2010 Aug 01; 70(15):6313-24.
    View in: PubMed
    Score: 0.032
  6. Polymer-enhanced adenoviral transduction of CAR-negative bladder cancer cells. Mol Pharm. 2009 Sep-Oct; 6(5):1612-9.
    View in: PubMed
    Score: 0.030
  7. Oxidative stress sensitizes bladder cancer cells to TRAIL mediated apoptosis by down-regulating anti-apoptotic proteins. J Urol. 2009 Sep; 182(3):1178-85.
    View in: PubMed
    Score: 0.029
  8. The role of protein synthesis in cell cycling and cancer. Mol Oncol. 2009 Dec; 3(5-6):402-8.
    View in: PubMed
    Score: 0.029
  9. Sorafenib and vorinostat kill colon cancer cells by CD95-dependent and -independent mechanisms. Mol Pharmacol. 2009 Aug; 76(2):342-55.
    View in: PubMed
    Score: 0.029
  10. MDA-7/IL-24-induced cell killing in malignant renal carcinoma cells occurs by a ceramide/CD95/PERK-dependent mechanism. Mol Cancer Ther. 2009 May; 8(5):1280-91.
    View in: PubMed
    Score: 0.029
  11. Combination therapy with TRAIL: Recent developments and potential pitfalls. Cancer Biol Ther. 2009 Jan; 8(1):81-3.
    View in: PubMed
    Score: 0.029
  12. Doxorubicin generates a proapoptotic phenotype by phosphorylation of elongation factor 2. Free Radic Biol Med. 2007 Nov 01; 43(9):1313-21.
    View in: PubMed
    Score: 0.026
  13. The histone deacetylase inhibitors depsipeptide and MS-275, enhance TRAIL gene therapy of LNCaP prostate cancer cells without adverse effects in normal prostate epithelial cells. Cancer Gene Ther. 2007 Mar; 14(3):327-34.
    View in: PubMed
    Score: 0.025
  14. Targeting the short form of cFLIP by RNA interference is sufficient to enhance TRAIL sensitivity in PC3 prostate carcinoma cells. Cancer Biol Ther. 2006 Dec; 5(12):1618-23.
    View in: PubMed
    Score: 0.025
  15. Doxorubicin increases the effectiveness of Apo2L/TRAIL for tumor growth inhibition of prostate cancer xenografts. BMC Cancer. 2005 Jan 07; 5:2.
    View in: PubMed
    Score: 0.022
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.